Xenon Pharmaceuticals (XENE) Receiving Somewhat Positive Media Coverage, Study Shows

Media stories about Xenon Pharmaceuticals (NASDAQ:XENE) have trended somewhat positive on Sunday, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Xenon Pharmaceuticals earned a news impact score of 0.15 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.8847018714092 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Separately, Zacks Investment Research raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, October 5th.

Xenon Pharmaceuticals (NASDAQ:XENE) traded up $0.20 during midday trading on Friday, reaching $2.55. Xenon Pharmaceuticals has a 1 year low of $2.10 and a 1 year high of $9.95.

In related news, Director Mohammad Azab bought 10,000 shares of the firm’s stock in a transaction on Friday, September 22nd. The shares were bought at an average price of $2.95 per share, with a total value of $29,500.00. Following the completion of the transaction, the director now directly owns 21,210 shares of the company’s stock, valued at approximately $62,569.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 9.40% of the company’s stock.

WARNING: This news story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://ledgergazette.com/2017/12/10/xenon-pharmaceuticals-xene-receiving-somewhat-positive-media-coverage-study-shows.html.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).

Insider Buying and Selling by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply